🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

5 more days until we get an update from $MDNA (.to) $MDNAF on the MDNA11 mono Trial It will be interesting to see if Medicenna has been able to enroll patients in the other cohorts besides melanoma and if they also have more data on the 120 µg/kg every 2 and 3 weeks

$AFMD #AACR2025 established as safe 720mg future #AFM24 optimized weekly dose should result in exposure levels exceeding the cutoff for the high exposure group as early as week 2 doi.org/10.1158/1538-7…

$MDNAF $MDNA.to Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting Combination of MDNA11 with KEYTRUDA in the dose escalation arm achieved an objective response rate (ORR) of 36% (5 of 14) in all tumor types enrolling in the Phase 2 expansion

$MDNAF / $MDNA.TO Very good data today. This in particular is VERY SIGNIFICANT: 52-year-old female with TMB-H/MSS colorectal cancer who previously progressed on two prior lines of chemotherapy achieved a confirmed PR. While off-study for 4 months, the patient continues to show

$MDNAF $MDNA.to Mono #MDNA11

$MDNAF $MDNA.to Combo #MDNA11

$MDNAF $MDNA.to Single agent #MDNA11 in MSI-H only 4 patients so far, but 1 cPR, 1 PR and 1 patient still on treatment

$MDNAF $MDNA.to #AACR2025 Poster ir.medicenna.com/static-files/0…

Jean P. Gelinas volsareback EM maddstone Wolfgang Kissel $AFMD Affimed shows higher exposure of #AFM24 is associated with higher response rate and PFS #NSCLC #AACR affimed.com/affimed-shows-…

$MDNAF $MDNA.to IL-13Rα2 tumor-targeted! Medicenna Presents Promising Preclinical Data from its First-in-Class Tumor Targeted and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the Annual 2025 AACR Meeting #AACR25 ir.medicenna.com/news-releases/…

IL-13R⍺2 positive cancers #MDNA113 "The combination of MDNA113’s tumor targeting and conditional activation represents a uniquely differentiated and potentially superior alternative to other anti-PD-1-IL-2 bispecifics currently in development." $MDNAF $MDNA (.to)

$MDNA $MDNAF Join Medicenna at the Bloom Burton & Co. Healthcare Investor Conference, where Dr. Fahar Merchant, President & CEO, will present key milestones and share our forward-looking strategy. 📍 Metro Toronto Convention Centre 🕝 May 5 at 2:30 PM ET 🔗 Webcast:

$MDNAF $MDNA.TO IL13 had a lot of interest in the AACR conferences from several pharma companies

$MDNAF $MDNA.TO At this week’s #BloomBurton25 conference, Dr. Fahar Merchant delivered an impactful presentation highlighting Medicenna’s groundbreaking advances in immunotherapy through its Superkine platform. 📜 Read the full deck at: ir.medicenna.com 📺 Replay: The

$MDNAF $MDNA.TO Medicenna Therapeutics to Present at the Emerging Growth Conference – May 21, 2025 at 1:10 PM ET Join us for a 30-minute live session, where Dr. Fahar Merchant will share the latest updates on Medicenna’s groundbreaking immunotherapy pipeline with investors. 📅

Interesting to see $MDNA.to $MDNAF's CEO focusing on the Anti-PD-1 Bi-Specific program MDNA113 & the interest in these programs are getting hot as we saw the $PFE's deal upfront of $1.25B for the Chinese company for its Anti-PD-1 /VGEF More deals to come!

$MDNAF $MDNA.TO Exciting new advances in Biotech! Medicenna's Medicenna new video miniseries just launched. Ep. 1 explains IL-2 & the future of immunotherapy. A must watch. Also available on YouTube: youtu.be/lkf39tSlsoU 🔗 Learn more: medicenna.com #Biotech

$MDNAF $MDNA.TO Medicenna is heading to Boston for #BIO2025 - the biggest biotech partnering event of the year! We’re eager to share our pipeline progress & connect with global leaders in #biotech, #oncology, and #immunotherapy. DM us to meet at the event or discuss

$MDNAF $MDNA.TO Imagine training your immune system to hunt cancer, making it stronger, smarter, and longer-lasting. We've done it. It's called MDNA11. ✅ Blocks immune-suppressing signals ✅ Turbocharges anti-cancer cells ✅ One dose every 2 weeks Watch the video and discover